https://biotechmorning.com/news/icon-san-antonio-clinical-research-unit-expansion Biotech Morning en 2026-05-14T14:16:07.658Z Why the Biggest CRO in the World Just Bet Big on San Antonio https://biotechmorning.com/news/lexicon-ceo-200m-pipeline-expansion Biotech Morning en 2026-05-14T14:15:17.721Z Lexicon's CEO Has $200M and a Wild Look in His Eye https://biotechmorning.com/news/beqalzi-sonrotoclax-fda-approval-mantle-cell-lymphoma Biotech Morning en 2026-05-14T14:14:25.502Z The Blood Cancer Drug That Picked Up Where Others Left Off https://biotechmorning.com/news/fosun-60m-aribio-alzheimers-option-deal Biotech Morning en 2026-05-14T14:13:36.142Z Fosun Just Bet $60M on an Alzheimer's Drug That Doesn't Work Like Anything Else https://biotechmorning.com/news/takeda-nausea-vomiting-0-for-4 Biotech Morning en 2026-05-14T14:12:42.366Z Takeda Can't Stop Striking Out in Nausea and Vomiting https://biotechmorning.com/news/assertio-bidding-war-sweetened-acquisition Biotech Morning en 2026-05-14T14:11:54.478Z The Bidding War That Turned a $18 Stock Into a $23.50 Payday https://biotechmorning.com/news/biogen-alzheimers-tau-drug-phase-3-despite-miss Biotech Morning en 2026-05-14T14:11:05.235Z Biogen's Alzheimer's Drug Failed Its Big Test. They're Going to Phase 3 Anyway. https://biotechmorning.com/news/us-biotechs-moving-trials-overseas-fda-upheaval Biotech Morning en 2026-05-14T14:10:11.315Z America's Biotechs Are Packing Their Bags. Here's Where They're Going. https://biotechmorning.com/news/valneva-layoffs-travel-vaccine-market-weakens Biotech Morning en 2026-05-13T14:15:59.470Z The Pandemic Promised a Vaccine Boom. Valneva Just Hit the Wall. https://biotechmorning.com/news/boehringer-immunitas-407m-inflammation-deal Biotech Morning en 2026-05-13T14:15:17.086Z Boehringer Just Paid Big for a Target Nobody's Heard Of https://biotechmorning.com/news/isomorphic-labs-2-1-billion-series-b Biotech Morning en 2026-05-13T14:14:26.978Z Alphabet's AI Drug Lab Just Raised More Than Most Biotechs Are Worth https://biotechmorning.com/news/pfizer-hympavzi-eu-approval-hemophilia-inhibitors Biotech Morning en 2026-05-13T14:13:46.316Z Pfizer Just Crashed the Hardest Party in Hemophilia https://biotechmorning.com/news/mbx-4291-once-monthly-obesity-shot Biotech Morning en 2026-05-13T14:13:03.789Z The Obesity Shot That Could Turn Monthly Into the New Weekly https://biotechmorning.com/news/lilly-299-bet-obesity-drug-price-war Biotech Morning en 2026-05-13T14:12:20.072Z Lilly's $299 Bet to Win the Obesity Drug Price War https://biotechmorning.com/news/car-t-autoimmune-first-fda-submission Biotech Morning en 2026-05-13T14:11:31.881Z The Cancer Therapy That Wants a Second Career https://biotechmorning.com/news/china-biopharma-out-licensing-explosion Biotech Morning en 2026-05-13T14:10:46.328Z China Just Became the World's Drug Store (and Washington Is Freaking Out) https://biotechmorning.com/news/us-biotechs-moving-trials-abroad-fda-upheaval Biotech Morning en 2026-05-13T14:09:55.972Z America's Biotechs Are Packing Their Bags. The FDA Should Be Worried.